AtriCure (ATRC) Hisse Özeti
AtriCure, Inc. kalp dokusunun cerrahi ablasyonu, sol atriyal apendiksin çıkarılması ve periferik sinirlerin ablasyonu yoluyla ağrının geçici olarak engellenmesine yönelik cihazların geliştirilmesi, üretimi ve Amerika Birleşik Devletleri, Asya-Pasifik ve uluslararası tıp merkezlerine satışı ile uğraşmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 3/6 |
| Geçmiş Performans | 3/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
ATRC Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AtriCure, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$40.15 |
| 52 Haftanın En Yüksek Seviyesi | US$43.18 |
| 52 Haftanın En Düşük Seviyesi | US$25.36 |
| Beta | 1.25 |
| 1 Aylık Değişim | 43.50% |
| 3 Aylık Değişim | 38.35% |
| 1 Yıllık Değişim | 14.39% |
| 3 Yıllık Değişim | -29.39% |
| 5 Yıllık Değişim | -50.72% |
| Halka arzdan bu yana değişim | 185.16% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jul 01
ATRC: Competitive Rollout And Index Inclusion Are Expected To Support Upside
Analysts have adjusted their AtriCure fair value estimate to $47.00 from $52.78, reflecting updated assumptions on growth, profitability, and future P/E in light of recent research that highlights both emerging AtriClip competition and confidence in the company's ability to defend its share and execute a targeted rollout strategy. Analyst Commentary Recent Street research on AtriCure focuses on how the company might respond to new competition for AtriClip while still supporting its current valuation framework.Analiz Makalesi • Jun 21
AtriCure (ATRC) Stock Could Be 45.4% Undervalued As Growth Narrative Faces A Cash Flow Test
AtriCure (ATRC) is back on investor watchlists after recent trading left the stock around $28.80, inviting fresh scrutiny of its valuation against a backdrop of mixed short term and longer term returns. See our latest analysis for AtriCure. The recent 1 day share price return of 6.2% contrasts with weaker longer term performance, with the year to date share price return down 26.7% and the 5 year total shareholder return down 64.1%, suggesting recent momentum is rebuilding from a lower...Recent updates
Anlatı Güncellemesi • Jul 01
ATRC: Competitive Rollout And Index Inclusion Are Expected To Support Upside
Analysts have adjusted their AtriCure fair value estimate to $47.00 from $52.78, reflecting updated assumptions on growth, profitability, and future P/E in light of recent research that highlights both emerging AtriClip competition and confidence in the company's ability to defend its share and execute a targeted rollout strategy. Analyst Commentary Recent Street research on AtriCure focuses on how the company might respond to new competition for AtriClip while still supporting its current valuation framework.Analiz Makalesi • Jun 21
AtriCure (ATRC) Stock Could Be 45.4% Undervalued As Growth Narrative Faces A Cash Flow Test
AtriCure (ATRC) is back on investor watchlists after recent trading left the stock around $28.80, inviting fresh scrutiny of its valuation against a backdrop of mixed short term and longer term returns. See our latest analysis for AtriCure. The recent 1 day share price return of 6.2% contrasts with weaker longer term performance, with the year to date share price return down 26.7% and the 5 year total shareholder return down 64.1%, suggesting recent momentum is rebuilding from a lower...
Anlatı Güncellemesi • Jun 17
ATRC: Accelerated BoxX-NoAF Trial And Firmer P E Frame Will Support Repricing
Analysts have nudged their average AtriCure price target higher by $2, citing recent research that points to slightly stronger revenue and margin expectations, which in turn support a modestly lower discount rate and P/E assumption. Analyst Commentary Recent research on AtriCure points to a more constructive tone, with bullish analysts highlighting factors they see as supportive of the latest price target adjustments and valuation assumptions.Anlatı Güncellemesi • Jun 03
ATRC: Raised Coverage And P E Outlook Will Support Bullish Repricing
Analysts have raised their AtriCure price target by $2, citing recent supportive research that points to a more constructive view on the stock and its long term assumptions around growth, margins, and future P/E levels. Analyst Commentary Recent research points to a more constructive stance on AtriCure, with bullish analysts emphasizing how current expectations for growth, margins, and future P/E levels could support the stock’s long term investment case.Anlatı Güncellemesi • May 19
ATRC: Product Moat And Clinical Data Will Support Bullish Repricing
Analysts have trimmed their fair value estimate for AtriCure to $55 from $64, reflecting updated assumptions for slightly softer revenue growth, a modestly lower profit margin outlook, and a reduced future P/E multiple, even as recent research points to ongoing product progress and a still supportive view from several firms despite rising competitive concerns. Analyst Commentary Recent research on AtriCure highlights a split in views, with some firms flagging competitive threats and others pointing to ongoing execution in sales, earnings, and product development as support for current valuations.
Anlatı Güncellemesi • May 01
ATRC: Clinical Strength And 2026 Profitability Are Expected To Offset New Competition
The updated analyst price target for AtriCure now reflects a modest valuation reset in the mid to high $50 range, as analysts weigh recent target cuts and rating downgrades against ongoing confidence in the company's product pipeline, clinical data strength, and prospects for durable revenue growth with improving profitability. Analyst Commentary Recent research has introduced a mix of optimism and caution around AtriCure, with bullish views on the product portfolio and clinical positioning sitting alongside fresh concerns about competition and long term growth durability.Anlatı Güncellemesi • Apr 17
ATRC: Clinical Moat And 2026 Profitability Are Expected To Withstand New Entrant
Narrative Update on AtriCure The updated analyst price target for AtriCure has edged down by about $0.23, reflecting a slightly higher discount rate and lower expected future P/E. Analysts are weighing new competitive risks against continued confidence in the company’s product pipeline, clinical data, and profitability progress.Anlatı Güncellemesi • Apr 02
ATRC: 2026 Guidance And Clinical Moat Are Expected To Outlast New Competition
Analysts have modestly reduced the AtriCure price target by $1.31 to $36.41. This reflects both lower published Street targets in response to emerging competition and continued confidence in revenue growth, margins, and the company’s clinical and product positioning.Anlatı Güncellemesi • Mar 19
ATRC: 2026 Guidance And Clinical Moat Will Confront Emerging Competition
Analysts have trimmed AtriCure's average price target by a few dollars to around the mid $50s. This reflects a mix of confidence in recent sales and EPS outperformance and product progress, tempered by concerns about emerging competition in left atrial appendage closure products and long term growth risks.Anlatı Güncellemesi • Mar 04
ATRC: 2026 Guidance And New Dual Energy Platform Will Shape Upside
Analysts have adjusted their outlook on AtriCure, with our updated fair value estimate moving from $36.00 to about $37.72. This change reflects a mix of lower Street price targets, concerns about emerging competition, and continued confidence in the company’s product progress, clinical data, and profitability trajectory.Anlatı Güncellemesi • Feb 18
ATRC: JPMorgan Downgrade And 2026 Profit Outlook Will Shape Risk Balance
Analysts have revised their AtriCure price target from $40.00 to $36.00, citing updated assumptions around discount rates, revenue growth, profit margins, and elevated future P/E expectations in light of recent research, including the JPMorgan downgrade. Analyst Commentary Recent commentary points to a more cautious stance on AtriCure, with the revised US$36.00 target reflecting what bearish analysts see as a need to factor in higher risk around execution, profitability, and future growth expectations.Anlatı Güncellemesi • Feb 04
ATRC: Dual Energy Platform Trial Progress Will Support Long Term Upside Potential
Analysts have adjusted their price targets on AtriCure, reflecting updated assumptions around discount rates, revenue growth, profit margins and a revised future P/E of 134.36x. Collectively, these factors support a fair value estimate of about $52.78 per share.Anlatı Güncellemesi • Jan 21
ATRC: Future Trial Progress Will Drive Confidence In Long Term Outlook
AtriCure's updated analyst price target has increased from US$50.00 to about US$52.78. Analysts cite adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E as the key drivers of this change.Anlatı Güncellemesi • Jan 06
ATRC: Dual Energy Ablation Breakthrough Will Drive Bullish Repricing
Analysts have maintained their price target on AtriCure at US$64.00, citing updated assumptions for slightly higher revenue growth, wider profit margins, a modestly higher discount rate, and a lower future P/E multiple as key inputs to their valuation work. What's in the News AtriCure announced successful first in human procedures using its dual energy platform that combines Pulsed Field Ablation with Advanced Radiofrequency Ablation, performed at Victorian Heart Hospital in Australia under Monash Health HREC approval (Key Developments).Anlatı Güncellemesi • Dec 15
ATRC: Dual Energy Platform And Noaf Trial Will Drive Bullish Repricing
Analysts have raised their price target on AtriCure by approximately 7 percent to 64 dollars per share, reflecting greater confidence in the company’s improving profit margin outlook and more favorable long term valuation assumptions, despite a slightly higher discount rate. What's in the News AtriCure reported successful first in human procedures with its dual energy ablation platform that combines Pulsed Field Ablation with Advanced Radiofrequency Ablation, achieving box lesion creation and pulmonary vein plus posterior wall isolation in under 60 seconds in the first two patients (company announcement).Analiz Makalesi • Dec 11
AtriCure, Inc.'s (NASDAQ:ATRC) 29% Share Price Surge Not Quite Adding Up
AtriCure, Inc. ( NASDAQ:ATRC ) shares have had a really impressive month, gaining 29% after a shaky period beforehand...Analiz Makalesi • Nov 01
AtriCure, Inc. (NASDAQ:ATRC) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
AtriCure, Inc. ( NASDAQ:ATRC ) defied analyst predictions to release its quarterly results, which were ahead of market...Analiz Makalesi • Aug 01
AtriCure, Inc. (NASDAQ:ATRC) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
AtriCure, Inc. ( NASDAQ:ATRC ) investors will be delighted, with the company turning in some strong numbers with its...Analiz Makalesi • Jul 08
AtriCure (NASDAQ:ATRC) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Jun 26
AtriCure: Profits And Operating Leverage Are Needed Here
Summary AtriCure has had impressive and sound growth over the past decade. The company has continued to post losses, even though relative losses are coming down. The combination of double-digit sales growth and a 3 times sales multiple looks compelling, yet further margin gains are required to drive appeal here. Read the full article on Seeking AlphaAnaliz Makalesi • May 01
AtriCure, Inc. (NASDAQ:ATRC) Screens Well But There Might Be A Catch
It's not a stretch to say that AtriCure, Inc.'s ( NASDAQ:ATRC ) price-to-sales (or "P/S") ratio of 3.1x seems quite...Analiz Makalesi • Apr 04
Is AtriCure (NASDAQ:ATRC) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Yeni Anlatı • Mar 22
cryoSPHERE+ And EnCompass Clamp Launches Will Accelerate Global Adoption
New product launches and international expansion, especially in Europe and China, are key drivers for AtriCure's projected revenue growth and market leadership.Analiz Makalesi • Jan 22
Revenues Tell The Story For AtriCure, Inc. (NASDAQ:ATRC) As Its Stock Soars 29%
AtriCure, Inc. ( NASDAQ:ATRC ) shares have continued their recent momentum with a 29% gain in the last month alone...Analiz Makalesi • Jan 15
Calculating The Fair Value Of AtriCure, Inc. (NASDAQ:ATRC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, AtriCure fair value estimate is US$35.69 With US$34.69 share...Analiz Makalesi • Dec 24
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Nov 06
A Piece Of The Puzzle Missing From AtriCure, Inc.'s (NASDAQ:ATRC) 28% Share Price Climb
Despite an already strong run, AtriCure, Inc. ( NASDAQ:ATRC ) shares have been powering on, with a gain of 28% in the...Analiz Makalesi • Nov 01
US$42.67 - That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After These Results
AtriCure, Inc. ( NASDAQ:ATRC ) defied analyst predictions to release its third-quarter results, which were ahead of...Analiz Makalesi • Oct 31
Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?
AtriCure, Inc. ( NASDAQ:ATRC ), is not the largest company out there, but it saw a significant share price rise of 71...Analiz Makalesi • Oct 02
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 43% Above Its Share Price
Key Insights AtriCure's estimated fair value is US$39.81 based on 2 Stage Free Cash Flow to Equity Current share price...Analiz Makalesi • Sep 06
Further Upside For AtriCure, Inc. (NASDAQ:ATRC) Shares Could Introduce Price Risks After 29% Bounce
AtriCure, Inc. ( NASDAQ:ATRC ) shareholders would be excited to see that the share price has had a great month, posting...Analiz Makalesi • Aug 02
Analysts Have Been Trimming Their AtriCure, Inc. (NASDAQ:ATRC) Price Target After Its Latest Report
There's been a notable change in appetite for AtriCure, Inc. ( NASDAQ:ATRC ) shares in the week since its...Seeking Alpha • Jul 25
AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care
Summary AtriCure, Inc. is a market leader in surgical solutions for atrial fibrillation, LAA management, and post-operative pain management, serving 2,000 hospitals globally. AtriCure's latest project involves expanding into the European market with innovative products, facing potential regulatory delays and market acceptance challenges. Despite facing competition from major players like Johnson & Johnson and Medtronic, AtriCure's strong revenue growth and innovative product lineup position it for continued success in the market. Read the full article on Seeking AlphaAnaliz Makalesi • Jul 18
AtriCure, Inc. (NASDAQ:ATRC) Soars 26% But It's A Story Of Risk Vs Reward
AtriCure, Inc. ( NASDAQ:ATRC ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...Analiz Makalesi • May 30
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, AtriCure fair value estimate is US$40.72 AtriCure's US$21.61...Analiz Makalesi • Apr 04
Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump
AtriCure, Inc. ( NASDAQ:ATRC ) shareholders won't be pleased to see that the share price has had a very rough month...Analiz Makalesi • Mar 14
Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Jan 21
Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues
When close to half the companies in the Medical Equipment industry in the United States have price-to-sales ratios (or...Analiz Makalesi • Nov 29
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analiz Makalesi • Sep 27
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price
Key Insights AtriCure's estimated fair value is US$84.48 based on 2 Stage Free Cash Flow to Equity Current share price...Hissedar Getirileri
| ATRC | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | 21.7% | 6.2% | 0.5% |
| 1Y | 14.4% | -14.2% | 16.5% |
Getiri vs. Endüstri: ATRC geçen yıl % -14.2 oranında getiri sağlayan US Medical Equipment sektörünü aştı.
Getiri vs Piyasa: ATRC geçen yıl boyunca % 16.5 oranında getiri sağlayan US Piyasası ile eşleşti.
Fiyat Oynaklığı
| ATRC volatility | |
|---|---|
| ATRC Average Weekly Movement | 7.0% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: ATRC son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: ATRC 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2000 | 1,350 | Mike Carrel | www.atricure.com |
AtriCure, Inc. kardiyak dokunun cerrahi ablasyonu, sol atriyal apendiksin çıkarılması ve periferik sinirlerin ablasyonu yoluyla ağrının geçici olarak engellenmesi için cihazların geliştirilmesi, üretimi ve Amerika Birleşik Devletleri, Asya-Pasifik ve uluslararası tıp merkezlerine satışı ile uğraşmaktadır. Tek kullanımlık tek kullanımlık radyo frekansı ürünleri olan Isolator Synergy Ablasyon Sistemi klempleri; kardiyak aritmilerin tedavisi için tek kullanımlık tek kullanımlık RF ürünleri olan çok işlevli kalemler ve doğrusal ablasyon cihazları; kullanıcının çeşitli uzunluklarda doğrusal ablasyonlar yapmasını sağlayan cryoICE Cryoablation Sistemi ve semptomatik, ilaca dirençli ve uzun süredir devam eden kalıcı atriyal fibrilasyonun tedavisinde kullanılan tek kullanımlık tek kullanımlık bir cihaz olan EPi-Sense Sistemleri sunmaktadır. Ayrıca, göğüs kafesinde hedeflenen interkostal periferik sinirlere kriyotermik enerji uygulayarak geçici ağrı kesici sağlayan cryoSPHERE probu; tek kullanımlık tek kullanımlık bir uygulayıcıya bağlı implante edilebilir bir cihaz olan AtriClip Sistemi; özellikle Cryo Nerve Block tedavisi için tasarlanmış bir kriyoablasyon cihazı olan cryoXT probları sunmaktadır; Yumuşak doku kapatma için bir çözüm olan LARIAT Sistemi; ablasyon için hedeflenen önemli anatomik yapılara erişim sağlamak üzere dokuları ayırmak için Lumitip disektörleri; klemplerin yerleştirilmesi için Glidepath kılavuzları ve EPi-Sense kateterlerine erişimi desteklemek için Subtle Kanülleri.
AtriCure, Inc. Temel Bilgiler Özeti
| ATRC temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$2.08b |
| Kazançlar(TTM) | US$10.55m |
| Gelir(TTM) | US$569.62m |
193.5x
F/K Oranı3.6x
P/S OranıATRC aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| ATRC gelir tablosu (TTM) | |
|---|---|
| Gelir | US$569.62m |
| Gelir Maliyeti | US$135.01m |
| Brüt Kâr | US$434.61m |
| Diğer Giderler | US$424.06m |
| Kazançlar | US$10.55m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 0.21 |
| Brüt Marj | 76.30% |
| Net Kâr Marjı | 1.85% |
| Borç/Özkaynak Oranı | 11.8% |
ATRC uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/30 13:48 |
| Gün Sonu Hisse Fiyatı | 2026/07/30 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
AtriCure, Inc. 19 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Charley Jones | Barrington Research Associates, Inc. |
| Marie Thibault | BTIG |
| Michael Gorman | BTIG |